

13. Februar 2020

ASCO-GU-Kongress: Bayer präsentiert neue Daten aus Onkologie-Portfolio

Daten aus dem wachsenden Onkologie-Portfolio von Bayer werden auf dem Krebs-Symposium der American Society of Clinical Oncology Genitourinary (ASCO GU) ab heute bis 15. Februar 2020 in San Francisco, Kalifornien (USA), vorgestellt. Zu Darolutamid werden neue Daten im Vergleich zu Enzalutamid vorgestellt: untersucht wurde der Einfluss beider Substanzen auf den zerebralen Blutfluss und die kognitiven Funktionen bei Männern mit nicht metastasiertem, kastrationsresistentem Prostatakrebs (nmCRPC).

Darolutamid, ein von Bayer und Orion Corporation gemeinsam entwickelter Androgenrezeptor-Inhibitor (ARI), ist bereits in den USA, Japan und Brasilien zugelassen und hat kürzlich vom Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP) der Europäischen Arzneimittelagentur die Empfehlung zur Zulassung für die Europäische Union erhalten.

Darüber hinaus werden weitere Forschungsergebnisse zu Radium-223-dichlorid präsentiert. Es werden 18 Präsentationen und Poster, darunter Analysen aus dem Klinikalltag, die die Sicherheit und Wirksamkeit von Radium-223 bestätigen, sowie neue Studien zu Kombinationstherapien mit Radium-223 bei Männern mit fortgeschrittenem Prostatakrebs vorgestellt.

Folgende Studien werden unter anderem auf dem ASCO-GU Kongress vorgestellt (alle Angaben Ortszeit):

Darolutamid

- Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers
 - o Abstract: 326, Poster Session A: Prostate Cancer; Board M10
 - o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
- INTREPId (INTermediate Risk Erektion Preservation Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer
 - o Abstract: TPS384, Trials in Progress Poster Session A: Prostate Cancer; Board Q4
 - o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr

Radium-223-dichlorid

- Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC) – Investigator initiated research (IIR)
 - o Abstract: 130, Poster Session A: Prostate Cancer; Board F10
 - o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
- Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
 - o Abstract: 32, Poster Session A: Prostate Cancer; Board A20
 - o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
- Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): a retrospective study of real-world clinical outcomes in patients (pts) with

metastatic castration-resistant prostate cancer (mCRPC)

- o Abstract: 50, Poster Session A: Prostate Cancer; Board B16
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Variance in symptom assessment between patient and caregiver: a prospective study of patients staged as metastatic prostate cancer – an interim analysis – IIR
- o Abstract: 56, Poster Session A: Prostate Cancer; Board B22
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints – IIR
- o Abstract: 125, Poster Session A: Prostate Cancer; Board F5
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Fracture rates in radium223 (Ra223) treated mCRPC patients (pts): A real-world analysis in 177 pts treated at a single community center 2010-2018
- o Abstract: 41, Poster Session A: Prostate Cancer; Board B7
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - PRINT: Prostate Cancer Intensive, Non-Cross Reactive Therapy for CRPC – Early Observations of Efficacy – IIR
- o Abstract: 89, Poster Session A: Prostate Cancer; Board D13
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - The National Radium-223 Dichloride Audit Group: data from patients in United Kingdom oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride – IIR
- o Abstract: 59, Poster Session A: Prostate Cancer; Board C3
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Results of the ADRRAD Trial of pelvic IMRT plus radium-223 in men with mHSPC metastatic to bone – IIR
- o Abstract: 136, Poster Session A: Prostate Cancer; Board F16
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.
- o Abstract: 121, Poster Session A: Prostate Cancer; Board F1
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Analysis of prevalence and prognostic implications of early versus delayed PSA declines during radium-223 (Ra223) treatment among men with metastatic castration-resistant prostate cancer (mCRPC)
- o Abstract: 117, Poster Session A: Prostate Cancer; Board E19
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Who is a bone-predominant patient to maximize clinical benefits of radium-223 dichloride?
- o Abstract: 47, Poster Session A: Prostate Cancer; Board B13
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC)
- o Abstract: 73, Poster Session A: Prostate Cancer; Board C17
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response
- o Abstract: TPS267, Trials in Progress Poster Session A: Prostate Cancer; Board P11
- o 13. Februar, 11:30 – 13:00 Uhr, 17:30 – 18:30 Uhr
 - Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration resistant prostate cancer (mCRPC): a U.S. tertiary oncology center analysis
- o Abstract: 223, Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers; Board B1
- o 14. Februar, 12:15 – 13:45 Uhr, 17:15 – 18:15 Uhr
 - Safety and effectiveness of radium-223 dichloride (Ra-223) in patients with mCRPC in real-world setting: A Japanese post-marketing study (PMS)
- o Abstract: 236, Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers; Board B14
- o 14. Februar, 12:15 – 13:45 Uhr, 17:15 – 18:15 Uhr

- Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience
 - o Abstract: 228, Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers; Board B6
 - o 14. Februar, 12:15 – 13:45 Uhr, 17:15 – 18:15 Uhr
- Prognostic factors that affect survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223
 - o Abstract: 225, Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers; Board B3
 - o 14. Februar, 12:15 – 13:45 Uhr, 17:15 – 18:15 Uhr

[Abstracts ASCO-GU](#)

Quelle: Bayer